Research Analysts Offer Predictions for ASND FY2025 Earnings

Ascendis Pharma A/S (NASDAQ:ASND) – Stock analysts at Cantor Fitzgerald lowered their FY2025 earnings estimates for shares of Ascendis Pharma A/S in a report issued on Tuesday, May 6th. Cantor Fitzgerald analyst L. Watsek now anticipates that the biotechnology company will post earnings per share of ($4.42) for the year, down from their prior forecast of ($2.72). Cantor Fitzgerald currently has a “Overweight” rating and a $200.00 price target on the stock. The consensus estimate for Ascendis Pharma A/S’s current full-year earnings is ($4.34) per share.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its earnings results on Thursday, May 1st. The biotechnology company reported ($1.66) EPS for the quarter, missing the consensus estimate of ($1.56) by ($0.10). The firm had revenue of $123.97 million during the quarter, compared to analyst estimates of $98.56 million.

A number of other equities research analysts have also commented on ASND. JPMorgan Chase & Co. increased their price objective on shares of Ascendis Pharma A/S from $200.00 to $245.00 and gave the stock an “overweight” rating in a report on Friday, May 2nd. Wedbush raised their price target on shares of Ascendis Pharma A/S from $181.00 to $212.00 and gave the company an “outperform” rating in a report on Friday, May 2nd. Morgan Stanley raised Ascendis Pharma A/S from an “equal weight” rating to an “overweight” rating and upped their price objective for the stock from $180.00 to $250.00 in a report on Monday, May 5th. Royal Bank of Canada boosted their target price on Ascendis Pharma A/S from $205.00 to $210.00 and gave the stock an “outperform” rating in a research report on Friday, May 2nd. Finally, Evercore ISI raised their price target on Ascendis Pharma A/S from $260.00 to $280.00 and gave the company an “outperform” rating in a report on Friday, May 2nd. One investment analyst has rated the stock with a hold rating and fifteen have given a buy rating to the company. Based on data from MarketBeat, Ascendis Pharma A/S currently has a consensus rating of “Moderate Buy” and an average target price of $216.07.

Ascendis Pharma A/S Stock Performance

Ascendis Pharma A/S stock opened at $151.25 on Thursday. Ascendis Pharma A/S has a 52 week low of $111.09 and a 52 week high of $183.00. The firm has a market cap of $9.22 billion, a P/E ratio of -21.30 and a beta of 0.41. The business’s fifty day moving average is $156.12 and its two-hundred day moving average is $141.37.

Institutional Trading of Ascendis Pharma A/S

Large investors have recently bought and sold shares of the business. Altfest L J & Co. Inc. bought a new position in Ascendis Pharma A/S in the first quarter valued at approximately $329,000. PNC Financial Services Group Inc. lifted its position in Ascendis Pharma A/S by 2.3% in the 1st quarter. PNC Financial Services Group Inc. now owns 8,578 shares of the biotechnology company’s stock valued at $1,337,000 after acquiring an additional 195 shares in the last quarter. Dearborn Partners LLC acquired a new position in Ascendis Pharma A/S in the 1st quarter worth $203,000. XTX Topco Ltd acquired a new stake in shares of Ascendis Pharma A/S in the 1st quarter valued at about $584,000. Finally, TD Asset Management Inc raised its stake in shares of Ascendis Pharma A/S by 1.1% in the 1st quarter. TD Asset Management Inc now owns 343,390 shares of the biotechnology company’s stock valued at $53,521,000 after purchasing an additional 3,738 shares during the period.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.